Impact of the COVID-19 pandemic on patients with primary immunodeficiency

Abdool Karim S.S. and De Oliveira T., 2021. New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications. N Engl J Med 384, 1866–1868. https://doi.org/10.1056/NEJMc2100362

Al Shaqaq A., Sham M., Abrego Fuentes L., Garkaby J., Willett Pachul J., Vong L., Upton J., Kim V., and Roifman C.M., 2023. The impact of COVID-19 infection in pediatric and adult patients with primary immunodeficiency: a single center analysis. LymphoSign Journal 10, 71–76. https://doi.org/10.14785/lymphosign-2023-0012

Alberts B., Johnson A., Lewis J., Raff M., Roberts K., and Walter P., 2002. Molecular biology of the cell, 4th ed. Garland Science, New York.

Al-Musa A., LaBere B., Habiballah S., Nguyen A.A., and Chou J., 2022. Advances in clinical outcomes: What we have learned during the COVID-19 pandemic. Journal of Allergy and Clinical Immunology 149, 569–578. https://doi.org/10.1016/j.jaci.2021.12.775

Amaya-Uribe L., Rojas M., Azizi G., Anaya J.-M., and Gershwin M.E., 2019. Primary immunodeficiency and autoimmunity: A comprehensive review. Journal of Autoimmunity 99, 52–72. https://doi.org/10.1016/j.jaut.2019.01.011

Ameratunga R., Leung E., Woon S.-T., Chan L., Steele R., Lehnert K., and Longhurst H., 2022. SARS-CoV-2 Omicron: Light at the End of the Long Pandemic Tunnel or Another False Dawn for Immunodeficient Patients? The Journal of Allergy and Clinical Immunology: In Practice 10, 2267–2273. https://doi.org/10.1016/j.jaip.2022.06.011

Amicone M., Borges V., Alves M.J., Isidro J., Zé-Zé L., Duarte S., Vieira L., Guiomar R., Gomes J.P., and Gordo I., 2022. Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution. Evolution, Medicine, and Public Health 10, 142–155. https://doi.org/10.1093/emph/eoac010

Andrews N., Stowe J., Kirsebom F., Toffa S., Rickeard T., Gallagher E., Gower C., Kall M., Groves N., O’Connell A.-M., Simons D., Blomquist P.B., Zaidi A., Nash S., Iwani Binti Abdul Aziz N., Thelwall S., Dabrera G., Myers R., Amirthalingam G., Gharbia S., Barrett J.C., Elson R., Ladhani S.N., Ferguson N., Zambon M., Campbell C.N.J., Brown K., Hopkins S., Chand M., Ramsay M., and Lopez Bernal J., 2022. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med 386, 1532–1546. https://doi.org/10.1056/NEJMoa2119451

Baang J.H., Smith C., Mirabelli C., Valesano A.L., Manthei D.M., Bachman M.A., Wobus C.E., Adams M., Washer L., Martin E.T., and Lauring A.S., 2021. Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. The Journal of Infectious Diseases 223, 23–27. https://doi.org/10.1093/infdis/jiaa666

Babaei M., Kanannejad Z., Sepahi N., and Alyasin S., 2022. The Effect of COVID-19 Pandemic on Patients with Primary Immunodeficiency: A Cohort Study. Iranian journal of medical sciences 47, 162–166. https://doi.org/10.30476/IJMS.2022.92862.2415

Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., McGettigan J., Khetan S., Segall N., Solis J., Brosz A., Fierro C., Schwartz H., Neuzil K., Corey L., Gilbert P., Janes H., Follmann D., Marovich M., Mascola J., Polakowski L., Ledgerwood J., Graham B.S., Bennett H., Pajon R., Knightly C., Leav B., Deng W., Zhou H., Han S., Ivarsson M., Miller J., and Zaks T., 2021. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine 384, 403–416. https://doi.org/10.1056/NEJMoa2035389

Bahremand, T., Yao, J.A., Mill, C., Piszczek, J., Grant, J.M., and Smolina, K., 2023. COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. The Lancet Regional Health – Americas 20. https://doi.org/10.1016/j.lana.2023.100461

Bai, Z., Cao, Y., Liu, W., and Li, J., 2021. The SARS-CoV-2 Nucleocapsid Protein and Its Role in Viral Structure, Biological Functions, and a Potential Target for Drug or Vaccine Mitigation. Viruses 13. https://doi.org/10.3390/v13061115

Bar-On Y.M., Goldberg Y., Mandel M., Bodenheimer O., Freedman L., Alroy-Preis S., Ash N., Huppert A., and Milo R., 2021. Protection against Covid-19 by BNT162b2 Booster across Age Groups. New England Journal of Medicine 385, 2421–2430. https://doi.org/10.1056/NEJMoa2115926

Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.-H., Zhang Y., Dorgham K., Philippot Q., Rosain J., Béziat V., Manry J., Shaw E., Haljasmägi L., Peterson P., Lorenzo L., Bizien L., Trouillet-Assant S., Dobbs K., de Jesus A.A., Belot A., Kallaste A., Catherinot E., Tandjaoui-Lambiotte Y., Le Pen J., Kerner G., Bigio B., Seeleuthner Y., Yang R., Bolze A., Spaan A.N., Delmonte O.M., Abers M.S., Aiuti A., Casari G., Lampasona V., Piemonti L., Ciceri F., Bilguvar K., Lifton R. P., Vasse M., Smadja D.M., Migaud M., Hadjadj J., Terrier B., Duffy D., Quintana-Murci L., van de Beek D., Roussel L., Vinh D.C., Tangye S.G., Haerynck F., Dalmau D., Martinez-Picado J., Brodin P., Nussenzweig M.C., Boisson-Dupuis S., Rodríguez-Gallego C., Vogt G., Mogensen T.H., Oler A.J., Gu J., Burbelo P.D., Cohen J.I., Biondi A., Bettini L.R., D’Angio M., Bonfanti P., Rossignol P., Mayaux J., Rieux-Laucat F., Husebye E.S., Fusco F., Ursini M. V., Imberti L., Sottini A., Paghera S., Quiros-Roldan E., Rossi C., Castagnoli R., Montagna D., Licari A., Marseglia G. L., Duval X., Ghosn J., Tsang J. S., Goldbach-Mansky R., Kis K., Lionakis M.S., Puel A., Zhang S.-Y., Holl S.M., Gorochov G., Jouanguy E., Rice C.M., Cobat A., Notarangelo L.D., Abel L., Su H.C., and Casanova J.-L., 2020. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 370, eabd4585. https://doi.org/10.1126/science.abd4585

Bourguiba R., Delplanque M., Vinit C., Ackermann F., Savey L., Grateau G., Hentgen V., and Georgin-lavialle S., 2021. Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area. Ann Rheum Dis 80, 539. https://doi.org/10.1136/annrheumdis-2020-218707

Brown, L.-A.K., Moran, E., Goodman, A., Baxendale, H., Bermingham, W., Buckland, M., AbdulKhaliq, I., Jarvis, H., Hunter, M., Karanam, S., Patel, A., Jenkins, M., Robbins, A., Khan, S., Simpson, T., Jolles, S., Underwood, J., Savic, S., Richter, A., Shields, A., Brown, M., and Lowe, D.M., 2022. Treatment of chronic or relapsing COVID-19 in immunodeficiency. Journal of Allergy and Clinical Immunology 149, 557-561.e1. https://doi.org/10.1016/j.jaci.2021.10.031

Byung Wook E. and Byung Ok K., 2023. COVID-19 in immunocompromised children and adolescents. Clin Exp Pediatr 66, 182–189. https://doi.org/10.3345/cep.2022.00878

Cameroni E., Bowen J.E., Rosen L.E., Saliba C., Zepeda S.K., Culap K., Pinto D., VanBlargan L.A., De Marco A., di Iulio J., Zatta F., Kaiser H., Noack J., Farhat N., Czudnochowski N., Havenar-Daughton C., Sprouse K.R., Dillen J.R., Powell A.E., Chen A., Maher C., Yin L., Sun D., Soriaga L., Bassi J., Silacci-Fregni C., Gustafsson C., Franko N.M., Logue J., Iqbal N.T., Mazzitelli I., Geffner J., Grifantini R., Chu H., Gori A., Riva A., Giannini O., Ceschi A., Ferrari P., Cippà P.E., Franzetti-Pellanda A., Garzoni C., Halfmann P.J., Kawaoka Y., Hebner C., Purcell L.A., Piccoli L., Pizzuto M.S., Walls A.C., Diamond M.S., Telenti A., Virgin H.W., Lanzavecchia A., Snell G., Veesler W., and Corti D., 2022. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664–670. https://doi.org/10.1038/s41586-021-04386-2

Castano-Jaramillo L.M., Yamazaki-Nakashimada M.A., O’Farrill-Romanillos P.M., Muzquiz Zermeño D., Scheffler Mendoza S.C., Venegas Montoya E., García Campos J.A., Sánchez-Sánchez L.M., Gámez González L.B., Ramírez López J.M., Bustamante Ogando J.C., Vásquez-Echeverri E., Medina Torres E.A., Lopez-Herrera G., Blancas Galicia L., Berrón Ruiz L., Staines-Boone A.T., Espinosa-Padilla S.E., Segura Mendez N.H., and Lugo Reyes S.O., 2021. COVID-19 in the Context of Inborn Errors of Immunity: a Case Series of 31 Patients from Mexico. Journal of Clinical Immunology 41, 1463–1478. https://doi.org/10.1007/s10875-021-01077-5

Cohen, B., Rubinstein, R., Gans, M.D., Deng, L., Rubinstein, A., and Eisenberg, R., 2021. COVID-19 infection in 10 common variable immunodeficiency patients in New York City. The Journal of Allergy and Clinical Immunology: In Practice 9, 504-507.e1. https://doi.org/10.1016/j.jaip.2020.11.006

Cousins, K., Sano, K., Lam, B., Röltgen, K., Bhavsar, D., Singh, G., McRae, O., Jeong, S., Aboelregal, N., Ho, H., Boyd, S., Krammer, F., and Cunningham-Rundles, C., 2023. Detection of SARS-CoV-2 Antibodies in Immunoglobulin Products. The Journal of Allergy and Clinical Immunology: In Practice 11, 2534-2541.e2. https://doi.org/10.1016/j.jaip.2023.05.005

Cui, Z., Liu, P., Wang, N., Wang, L., Fan, K., Zhu, Q., Wang, K., Chen, R., Feng, R., Jia, Z., Yang, M., Xu, G., Zhu, B., Fu, W., Chu, T., Feng, L., Wang, Y., Pei, X., Yang, P., Xie, X.S., Cao, L., Cao, Y., and Wang, X., 2022. Structural and functional characterizations of infectivity and immune evasion of SARS-CoV-2 Omicron. Cell 185, 860-871.e13. https://doi.org/10.1016/j.cell.2022.01.019

Delavari S., Abolhassani H., Abolnezhadian F., Babaha F., Iranparast S., Ahanchian H., Moazzen N., Nabavi,M., Arshi S., Fallahpour,M., Bemanian M.H., Shokri S., Momen T., Sadeghi-Shabestari M., Molatefi R., Shirkani A., Vosughimotlagh A., Safarirad M., Sharifzadeh M., Pashangzadeh S., Salami F., Shirmast P., Rezaei A., Shad T.M., Mohraz M., Rezaei N., Hammarström L., Yazdani R., and Aghamohamamdi A., 2021. Impact of SARS-CoV-2 Pandemic on Patients with Primary Immunodeficiency. Journal of Clinical Immunology 41, 345–355. https://doi.org/10.1007/s10875-020-00928-x

Deyà-Martínez A., García-García A., Gonzalez-Navarro E.A., Yiyi L., Vlagea A., Jordan I., Fumadó V., Fortuny C., Español M., Launes C., Esteve-Solé A., Juan M., Pascal M., and Alsina L., 2021. COVID-19 in children and young adults with moderate/severe inborn errors of immunity in a high burden area in pre-vaccine era. Clinical Immunology 230, 108821. https://doi.org/10.1016/j.clim.2021.108821

Díez J.-M., Romero C., and Gajardo R., 2020. Currently Available Intravenous Immunoglobulin Contains Antibodies Reacting Against Severe Acute Respiratory Syndrome Coronavirus 2 Antigens. Immunotherapy 12, 571–576. https://doi.org/10.2217/imt-2020-0095

Drabe C.H., Hansen A.-B.E., Rasmussen L.D., Larsen O.D., Møller A., Mogensen T.H., Helweg-Larsen J., and Katzenstein T.L., 2021. Low morbidity in Danish patients with common variable immunodeficiency disorder infected with severe acute respiratory syndrome coronavirus 2. Infectious Diseases 53, 953–958. https://doi.org/10.1080/23744235.2021.1957144

Drzymalla, E., Moonesinghe, R., Kolor, K., Khoury, M.J., Schieber, L., and Gundlapalli, A.V., 2023. Severity Outcomes among Adult Patients with Primary Immunodeficiency and COVID-19 Seen in Emergency Departments, United States, April 2020 – August 2021. Journal of Clinical Medicine 12. https://doi.org/10.3390/jcm12103516

Ebinger J.E., Achamallah N., Ji H., Claggett B.L., Sun N., Botting P., Nguyen T.-T., Luong E., Kim E.H., Park E., Liu Y., Rosenberry R., Matusov Y., Zhao S., Pedraza I., Zaman T., Thompson M., Raedschelders K., Berg A.H., Grein J.D., Noble P.W., Chugh S.S., Merz C.N.B., Marbán E., Van Eyk J.E., Solomon S.D., Albert C.M., Chen P., and Cheng S., 2020. Pre-existing traits associated with Covid-19 illness severity. PLOS ONE 15, e0236240. https://doi.org/10.1371/journal.pone.0236240

ECDC SARS-CoV-2 variants [WWW Document], 2021. URL https://www.ecdc.europa.eu/en/covid-19/variants-concern (accessed 9.4.24).

Esenboga S., Ocak M., Akarsu A., Bildik H.N., Cagdas D., Iskit A.T., and Tezcan I., 2021. COVID-19 in Patients with Primary Immunodeficiency. Journal of Clinical Immunology 41, 1515–1522. https://doi.org/10.1007/s10875-021-01065-9

Evans R.A., Dube S., Lu Y., Yates M., Arnetorp S., Barnes E., Bell S., Carty L., Evans K., Graham S., Justo N., Moss P., Venkatesan S., Yokota R., Ferreira C., McNulty R., Taylor S., and Quint J.K., 2023. Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. The Lancet Regional Health - Europe 35, 100747. https://doi.org/10.1016/j.lanepe.2023.100747

Farcet M.R., Karbiener M., Schwaiger J., Ilk R., and Kreil T.R., 2022. Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic. The Journal of Infectious Diseases 226, 1357–1361. https://doi.org/10.1093/infdis/jiab142

Fernando P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., Bailey R., Swanson KA., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck R.W., Hammitt L.L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D.B., Mather S., Dormitzer P.R., Şahin U., Jansen K.U., and Gruber W., 2020. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of Medicine 383, 2603–2615. https://doi.org/10.1056/NEJMoa2034577

Freeman D., Loe B.S., Chadwick A., Vaccari C., Waite F., Rosebrock L., Jenner L., Petit A., Lewandowsky S., Vanderslott S., Innocenti S., Larkin M., Giubilini A., Yu L.-M., McShane H., Pollard A.J., and Lambe S., 2022. COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychological Medicine 52, 3127–3141. https://doi.org/10.1017/S0033291720005188

Fricker C.R., Crabb J.H., and Tzipori S., 1998. Water-borne Cryptosporidiosis: Detection Methods and Treatment Options. Academic Press. https://doi.org/10.1016/S0065-308X(08)60123-2

Garcia-Beltran, W.F., St. Denis, K.J., Hoelzemer, A., Lam, E.C., Nitido, A.D., Sheehan, M.L., Berrios, C., Ofoman, O., Chang, C.C., Hauser, B.M., Feldman, J., Roederer, A.L., Gregory, D.J., Poznansky, M.C., Schmidt, A.G., Iafrate, A.J., Naranbhai, V., and Balazs, A.B., 2022. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 185, 457-466.e4. https://doi.org/10.1016/j.cell.2021.12.033

Gargano J.W., Wallace M., Hadler S.C., Langley G., Su J.R., Oster M.E., Broder K.R., Gee J., Weintraub E., Shimabukuro T., Scobie H.M., Moulia D., Markowitz L.E., Wharton M., McNally V.V., Romero J.R., Talbot H.K., Lee G.M., Daley M.F., and Oliver S.E., 2021. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021. MMWR Morb. Mortal. Wkly. Rep. 70, 977–982. https://doi.org/10.15585/mmwr.mm7027e2

Garkaby J., Willett Pachul J., Scott O., Abrego Fuentes L., Vong L., Upton J.E.M., Kim V.H.D., and Roifman C.M., 2023. Favorable outcome of COVID-19 in pediatric patients with primary immunodeficiency. Pediatric Allergy and Immunology 34, e13928. https://doi.org/10.1111/pai.13928

Goudouris E.S., Pinto-Mariz F., Mendonça L.O., Aranda C.S., Guimarães R.R., Kokron C., Barros M.T., Anísio F., Alonso M.L.O., Marcelino F., Valle S.O.R., Junior S.D., Barreto I.D.P., Ferreira J.F.S., Roxo-Junior P., do Rego Silva A.M., Campinhos F.L., Bonfim C., Loth G., Fernandes J.F., Garcia J.L., Capelo A., Takano O.A., Nadaf M.I.V., Toledo E.C., Cunha L.A.O., Di Gesu R.S.W., Schidlowski L., Fillipo P., Bichuetti-Silva D.C., Soldateli G., Ferraroni N.R., de Oliveira Dantas E., Pestana S., Mansour E., Ulaf R.G., Prando C., Condino-Neto A., and Grumach A.S., 2021. Outcome of SARS-CoV-2 Infection in 121 Patients with Inborn Errors of Immunity: A Cross-Sectional Study. Journal of Clinical Immunology 41, 1479–1489. https://doi.org/10.1007/s10875-021-01066-8

Greenmyer J.R. and Joshi A.Y., 2022. COVID-19 in CVID: a Case Series of 17 Patients. Journal of Clinical Immunology 42, 29–31. https://doi.org/10.1007/s10875-021-01150-z

Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A., and Eichinger S., 2021. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine 384, 2092–2101. https://doi.org/10.1056/NEJMoa2104840

Gröning, R., Walde, J., Ahlm, C., Forsell, M.N.E., Normark, J., and Rasmuson, J., 2024. Intravenous immunoglobulin therapy for COVID-19 in immunocompromised patients: A retrospective cohort study. International Journal of Infectious Diseases 144. https://doi.org/10.1016/j.ijid.2024.107046

Hanna, J.J., Geresu, L.B., Diaz, M.I., Ho, M., Casazza, J.A., Pickering, M.A., Lanier, H.D., Radunsky, A.P., Cooper, L.N., Saleh, S.N., Bedimo, R.J., Most, Z.M., Perl, T.M., Lehmann, C.U., Turer, R.W., Chow, J.Y., and Medford, R.J., 2023. Risk factors for SARS-CoV-2 infection and severe outcomes among people with human immunodeficiency virus: cohort study. Open Forum Infectious Diseases 10, ofad400. https://doi.org/10.1093/ofid/ofad400

Ho, H., Mathew, S., Peluso, M.J., and Cunningham-Rundles, C., 2021. Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City. The Journal of Allergy and Clinical Immunology: In Practice 9, 490-493.e2. https://doi.org/10.1016/j.jaip.2020.09.052

Hong Q., Han W., Li J., Xu S., Wang Y., Xu C., Li Z., Wang Y., Zhang C., Huang Z., and Cong Y., 2022. Molecular basis of receptor binding and antibody neutralization of Omicron. Nature 604, 546–552. https://doi.org/10.1038/s41586-022-04581-9

Hori S., Nomura T., and Sakaguchi S., 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057–1061. https://doi.org/10.1126/science.1079490

Janeway, C.A., Travers, P., Walport, M., and Shlomchik, M.J., 2001. Immunobiology: the immune system in health and disease; [animated CD-ROM inside], 5th ed. Garland Publ. [u.a.], New York, NY.

Karakoc Aydiner E., Bilgic Eltan S., Babayeva R., Aydiner O., Kepenekli E., Kolukisa B., Sefer A.P., Yalcin Gungoren E., Karabiber E., Yucel E.O., Ozdemir O., Kiykim A., Artac H., Yakici N., Yalcin K., Cokugras H., Celkan T.T., Orhan F., Yesilipek M.A., Baris S., and Ozen A., 2022. Adverse COVID-19 outcomes in immune deficiencies: Inequality exists between subclasses. Allergy 77, 282–295. https://doi.org/10.1111/all.15025

Kinoshita H., Durkee-Shock J., Jensen-Wachspress M., Kankate V.V., Lang H., Lazarski C.A., Keswani A., Webber K.C., Montgomery-Recht K., Walkiewicz M., Notarangelo L.D., Burbelo P.D., Fuss I., Cohen J.I., Bollard C.M., and Keller M.D., 2021. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency. Journal of Clinical Immunology 41, 1146–1153. https://doi.org/10.1007/s10875-021-01046-y

Kołtan S., Ziętkiewicz M., Grześk E., Becht R., Berdej-Szczot E., Cienkusz M., Ewertowska M., Heropolitańska-Pliszka E., Krysiak N., Lewandowicz-Uszyńska A., Mach-Tomalska M., Matyja-Bednarczyk A., Milchert M., Napiorkowska-Baran K., Pieniawska-Śmiech K., Pituch-Noworolska A., Renke J., Roliński J., Rywczak I. G., Stelmach-Gołdyś A., Strach M., Suchanek H., Sulicka-Grodzicka J., Szczawińska-Popłonyk A., Tokarski S., Więsik-Szewczyk E., Wolska-Kuśnierz B., Zeman K., and Pac M., 2022. COVID-19 in unvaccinated patients with inborn errors of immunity—polish experience. Frontiers in Immunology 13. https://doi.org/10.3389/fimmu.2022.953700

Korobova, Z.R., Arsentieva, N.A., Liubimova, N.E., Batsunov, O.K., Dedkov, V.G., Gladkikh, A.S., Sharova, A.A., Adish, Z., Chernykh, E.I., Kaschenko, V.A., Ratnikov, V.A., Gorelov, V.P., Stanevich, O.V., Kulikov, A.N., Pevtsov, D.E., and Totolian, A.A., 2022. Cytokine Profiling in Different SARS-CoV-2 Genetic Variants. International Journal of Molecular Sciences 23. https://doi.org/10.3390/ijms232214146

Kurosaki T., Kometani K., and Ise W., 2015. Memory B cells. Nature Reviews Immunology 15, 149–159. https://doi.org/10.1038/nri3802

Kuster, J.K., Unlu, S., Makin, T.A., Par-Young, J., Simonov, M., Shafi, S., Balanda, M., Randolph, C., Steele, R., Hsu, F.I., Price, C., Kohli-Pamnani, A., Borish, L., Lawrence, M.G., Kang, I., and Shin, J.J., 2022. Low IgG trough and lymphocyte subset counts are associated with hospitalization for COVID-19 in patients with primary antibody deficiency. The Journal of Allergy and Clinical Immunology: In Practice 10, 633-636.e3. https://doi.org/10.1016/j.jaip.2021.11.030

Lanari M., Vandini S., Capretti M.G., Lazzarotto T., and Faldella G., 2014. Respiratory Syncytial Virus Infections in Infants Affected by Primary Immunodeficiency. Journal of Immunology Research 2014, 850831. https://doi.org/10.1155/2014/850831

Liu, Y., and Rocklöv, J., 2022. The effective reproductive number of the Omicron variant of SARS-CoV-2 is several times relative to Delta. Journal of Travel Medicine 29, taac037. https://doi.org/10.1093/jtm/taac037

Ljungquist O., Lundgren M., Iliachenko E., Månsson F., Böttiger B., Landin-Olsson M., Wikén C., Rosendal E., Överby A.K., Wigren B.J., Forsell M.N.E., Kjeldsen-Kragh J., Rasmussen M., Kahn F., and Holm K., 2022. Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases. Infectious Diseases 54, 283–291. https://doi.org/10.1080/23744235.2021.2013528

Luo M., Guo L., Yu M., Jiang W., and Wang H., 2020. The psychological and mental impact of coronavirus disease 2019 (COVID-19) on medical staff and general public – A systematic review and meta-analysis. Psychiatry Research 291, 113190. https://doi.org/10.1016/j.psychres.2020.113190

Malahe, S.R.K., Hoek, R.A.S., Dalm, V.A.S.H., Broers, A.E.C., den Hoed, C.M., Manintveld, O.C., Baan, C.C., van Deuzen, C.M., Papageorgiou, G., Bax, H.I., Van Kampen, J.J., Hellemons, M.E., Kho, M.M.L., de Vries, R.D., Molenkamp, R., Reinders, M.E.J., and Rijnders, B.J.A., 2022. Clinical characteristics and outcome of immunocompromised patients with COVID-19 caused by the Omicron variant: a prospective observational study. medRxiv 2022.04.25.22273197. https://doi.org/10.1101/2022.04.25.22273197

Marcus N., Frizinsky S., Hagin D., Ovadia A., Hanna S., Farkash M., Maoz-Segal R., Agmon-Levin N., Broides A., Nahum A., Rosenberg E., Kuperman A.A., Dinur-Schejter Y., Berkun Y., Toker O., Goldberg S., Confino-Cohen R., Scheuerman O., Badarneh B., Epstein-Rigbi N., Etzioni A., Dalal I., and Somech R., 2021. Minor Clinical Impact of COVID-19 Pandemic on Patients With Primary Immunodeficiency in Israel. Frontiers in Immunology 11. https://doi.org/10.3389/fimmu.2020.614086

Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., and Katzourakis A., 2023. The evolution of SARS-CoV-2. Nature Reviews Microbiology 21, 361–379. https://doi.org/10.1038/s41579-023-00878-2

Matuozzo D., Talouarn E., Marchal A., Zhang P., Manry J., Seeleuthner Y., Zhang Y., Bolze A., Chaldebas M., Milisavljevic B., Gervais A., Bastard P., Asano T., Bizien L., Barzaghi F., Abolhassani H., Abou Tayoun A., Aiuti A., Alavi Darazam I., Allende L. M., Alonso-Arias R., Arias A. A., Aytekin G., Bergman P., Bondesan S., Bryceson Y. T., Bustos I. G., Cabrera-Marante O., Carcel S., Carrera P., Casari G., Chaïbi K., Colobran R., Condino-Neto A., Covill L. E., Delmonte O. M., El Zein L., Flores C., Gregersen P. K., Gut M., Haerynck F., Halwani R., Hancerli S., Hammarström L., Hatipoğlu N., Karbuz A., Keles S., Kyheng C., Leon-Lopez R., Franco J. L., Mansouri D., Martinez-Picado J., Metin Akcan O., Migeotte I., Morange P.-E., Morelle G., Martin-Nalda A., Novelli G., Novelli A., Ozcelik T., Palabiyik F., Pan-Hammarström Q., de Diego R. P., Planas-Serra L., Pleguezuelo D. E., Prando C., Pujol A., Reyes L. F., Rivière J. G., Rodriguez-Gallego C., Rojas J., Rovere-Querini P., Schlüter A., Shahrooei M., Sobh A., Soler-Palacin P., Tandjaoui-Lambiotte Y., Tipu I., Tresoldi C., Troya J., van de Beek D., Zatz M., Zawadzki P., Al-Muhsen S. Z., Alosaimi M. F., Alsohime F. M., Baris-Feldman H., Butte M. J., Constantinescu S. N., Cooper M. A., Dalgard C. L., Fellay J., Heath J. R., Lau Y.-L., Lifton R. P., Maniatis T., Mogensen T. H., von Bernuth H., Lermine A., Vidaud M., Bol,A., Deleuze J.-F., Nussbaum R., Kahn-Kirby A., Mentre F., Tubiana S., Gorochov G., Tubach F., and Hausfater F.COVID Human Genetic Effort, COVIDeF Study Group, French COVID Cohort Study Group, CoV-Contact Cohort, COVID-STORM Clinicians, COVID Clinicians, Orchestra Working Group, Amsterdam UMC Covid-19 Biobank, NIAID-USUHS COVID Study Group, Meyts I., Zhang S.-Y., Puel A., Notarangelo L.D., Boisson-Dupuis S., Su H.S., Boisson B., Jouanguy E., Casanova J.-L., Zhang Q., Abel L., and Cobat A. 2023. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Genome Medicine 15, 22. https://doi.org/10.1186/s13073-023-01173-8

Meyts I., Bucciol G., Quinti I., Neven B., Fischer A., Seoane E., Lopez-Granados E., Gianelli C., Robles-Marhuenda A., Jeandel P.-Y., Paillard C., Sankaran V.G., Demirdag Y.Y., Lougaris V., Aiuti A., Plebani A., Milito C., Dalm V.A.S.H., Guevara-Hoyer K., Sánchez-Ramón S., Bezrodnik L., Barzaghi F., Gonzalez-Granado L.I., Hayman G.R., Uzel G., Mendonça L.O., Agostini C., Spadaro G., Badolato R., Soresina A., Vermeulen F., Bosteels C., Lambrecht B.N., Keller M., Mustillo P.J., Abraham R.S., Gupta S., Ozen A., Karakoc-Aydiner E., Baris S., Freeman A. F., Yamazaki-Nakashimada M., Scheffler-Mendoza S., Espinosa-Padilla S., Gennery A.R., Jolles S., Espinosa Y., Poli M.C., Fieschi C., Hauck F., Cunningham-Rundles C., Mahlaoui N., Warnatz K., Sullivan K.E., and Tangye S.G., 2021. Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. Journal of Allergy and Clinical Immunology 147, 520–531. https://doi.org/10.1016/j.jaci.2020.09.010

Milito C., Lougaris V., Giardino G., Punziano A., Vultaggio A., Carrabba M., Cinetto F., Scarpa R., Delle Piane R.M., Baselli L., Ricci S., Rivalta B., Conti F., Marasco C., Marzollo A., Firinu D., Pulvirenti F., Lagnese G., Vivarelli E., Cancrini C., Martire B., Danieli M.G., Pession A., Vacca A., Azzari C., Fabio G., Matucci A., Soresina A.R., Agostini C., Spadaro G., Badolato R., Cicalese M. P., Aiuti A., Plebani A., Pignata C., and Quinti I., 2021. Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity. The Journal of Allergy and Clinical Immunology: In Practice 9, 2904-2906.e2. https://doi.org/10.1016/j.jaip.2021.04.017

Milota T., Sobotkova M., Smetanova J., Bloomfield M., Vydlakova J., Chovancova Z., Litzman J., Hakl R., Novak J., Malkusova I., Hanzlikova J., Jilek D., Hutyrova B., Novak V., Krcmova I., Sediva A., and Kralickova P., 2022. Risk factors for severe COVID-19 and hospital admission in patients with inborn errors of immunity - results from a multicenter nationwide study. Frontiers in Immunology 13.

Mingaleeva R.N., Nigmatulina N.A., Sharafetdinova L.M., Romozanova A.M., Gabdoulkhakova A.G., Filina Y.V., Shavaliyev R.F., Rizvanov A.A., and Miftakhova R.R., 2022. Biology of the SARS-CoV-2 Coronavirus. Biochemistry (Moscow) 87, 1662–1678. https://doi.org/10.1134/S0006297922120215

Mira E., Yarce O.A., Ortega C., Fernández S., Pascual N.M., Gómez C., Alvarez M.A., Molina I.J., Lama R., and Santamaria M., 2020. Rapid recovery of a SARS-CoV-2–infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma. The Journal of Allergy and Clinical Immunology: In Practice 8, 2793–2795. https://doi.org/10.1016/j.jaip.2020.06.046

Nevejan L., Ombelet S., Laenen L., Keyaerts E., Demuyser T., Seyler L., Soetens O., Van Nedervelde E., Naesens R., Geysels D., Verstrepen W., Cattoir L., Martens S., Michel C., Mathieu E., Reynders M., Evenepoel A., Hellemans J., Vanhee M., Magerman K., Maes J., Matheeussen V., Boogaerts H., Lagrou K., Cuypers L., and André E., 2022. Severity of COVID-19 among Hospitalized Patients: Omicron Remains a Severe Threat for Immunocompromised Hosts. Viruses 14. https://doi.org/10.3390/v14122736

Nyberg T., Ferguson N.M., Nash S.G., Webster H.H., Flaxman S., Andrews N., Hinsley W., Bernal J.L., Kall M., Bhatt S., Blomquist P., Zaidi A., Volz E., Aziz N.A., Harman K., Funk S., Abbott S., Nyberg T., Ferguson N.M., Nash S.G., Webster H.H., Flaxman S., Andrews N., Hinsley W., Lopez Bernal J., Kall M., Bhatt S., Blomquist P., Zaidi A., Volz E., Abdul Aziz N., Harman K., Funk S., Abbott S., Hope R., Charlett A., Ch,M., Ghani A.C., Seaman S.R., Dabrera G., De Angelis D., Presanis A. M., and Thelwall S., 2022. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. The Lancet 399, 1303–1312. https://doi.org/10.1016/S0140-6736(22)00462-7

Olivé-Cirera G.Fonseca E.Cantarín-Extremera V.Vázquez-López M.Jiménez-Legido M.González-Álvarez V.Ribeiro-Constante J.Camacho-Salas A.Martí I.Cancho-Candela R.Martínez-González M.J.Saiz A.Armangué T. and Spanish Study Group NeuroimmunoPed-Covid, 2022. Impact of COVID-19 in immunosuppressed children with neuroimmunologic disorders. Neurol Neuroimmunol Neuroinflamm 9, e1101. https://doi.org/10.1212/NXI.0000000000001101

Pham, M.N., Murugesan, K., Banaei, N., Pinsky, B.A., Tang, M., Hoyte, E., Lewis, D.B., and Gernez, Y., 2022. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. Journal of Allergy and Clinical Immunology 149, 907-911.e3. https://doi.org/10.1016/j.jaci.2021.11.022

Pulvirenti, F., Cinetto, F., Milito, C., Bonanni, L., Pesce, A.M., Leodori, G., Garzi, G., Miglionico, M., Tabolli, S., and Quinti, I., 2020. Health-related quality of life in common variable immunodeficiency Italian patients switched to remote assistance during the COVID-19 pandemic. The Journal of Allergy and Clinical Immunology: In Practice 8, 1894-1899.e2. https://doi.org/10.1016/j.jaip.2020.04.003

Quinti, I., Lougaris, V., Milito, C., Cinetto, F., Pecoraro, A., Mezzaroma, I., Mastroianni, C.M., Turriziani, O., Bondioni, M.P., Filippini, M., Soresina, A., Spadaro, G., Agostini, C., Carsetti, R., and Plebani, A., 2020. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. Journal of Allergy and Clinical Immunology 146, 211-213.e4. https://doi.org/10.1016/j.jaci.2020.04.013

Rahman M.M., Chisty M.A., Alam M.A., Sakib M.S., Quader M.A., Shobuj I.A., Halim M.A., and Rahman F., 2022. Knowledge, attitude, and hesitancy towards COVID-19 vaccine among university students of Bangladesh. PLOS ONE 17, e0270684. https://doi.org/10.1371/journal.pone.0270684

Rezaei, N., Hedayat, M., Aghamohammadi, A., and Nichols, K.E., 2011. Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies. Journal of Allergy and Clinical Immunology 127, 1329-1341.e2. https://doi.org/10.1016/j.jaci.2011.02.047

Roifman C.M., 2020. Managing primary immunodeficiency during the COVID-19 pandemic. LymphoSign Journal 7, 85–89. https://doi.org/10.14785/lymphosign-2020-0009

Roifman C.M. and Vong L., 2021. COVID-19 post-vaccination recommendations for primary immunodeficiency. LymphoSign Journal 8, 69–74. https://doi.org/10.14785/lymphosign-2021-0023

Romero C., Díez J.M., and Gajardo R., 2021. Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products. The Lancet Infectious Diseases 21, 765–766. https://doi.org/10.1016/S1473-3099(21)00059-1

Ruffner M.A., Sullivan K.E., and Henrickson S.E., 2017. Recurrent and Sustained Viral Infections in Primary Immunodeficiencies. Frontiers in Immunology 8.

Saddof J., Glenda G., An V., Vicky C., Georgi S., Beatriz G., Goepfert P.A., Carla T., Hein F., Bart S., Offergeld K., Scheper G., Taylor K.L., Robb M.L., Treanor J., Barouch D. H., Stoddard J., Ryser M.F., Marovich M.A., Neuzil K.M., Corey L., Cauwenberghs N., Tanner T., Hardt K., Ruiz-Guiñazú J., Le Gars M., Schuitemaker H., Van Hoof J., Struyf F., and Douoguih M., 2021. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. New England Journal of Medicine 384, 2187–2201. https://doi.org/10.1056/NEJMoa2101544

Sakaguchi S., Miyara M., Costantino C.M., and Hafler D.A., 2010. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10, 490–500. https://doi.org/10.1038/nri2785

Sakuramoto K., Wada D., Maruyama S., Muroya T., Saito F., Nakamori Y., and Kuwagata Y., 2024. Evaluation of characteristics and prognosis of COVID-19 patients requiring invasive mechanical ventilation during dominance of nonvariant, alpha, delta, and omicron variants in tertiary hospitals of Japan. BMC Infectious Diseases 24, 223. https://doi.org/10.1186/s12879-024-09131-4

Salari N., Hosseinian-Far A., Jalali R., Vaisi-Raygani A., Rasoulpoor Shna, Mohammadi M., Rasoulpoor Shabnam, and Khaledi-Paveh B., 2020. Prevalence of stress, anxiety, depression among the general population during the COVID-19 pandemic: a systematic review and meta-analysis. Globalization and Health 16, 57. https://doi.org/10.1186/s12992-020-00589-w

Sardinha, D.M., do Socorro Pompeu de Loiola, R., Ferreira, A.L. da S., de Sá, C.A.F., Rodrigues, Y.C., Lima, K.V.B., e Guimarães, R.J. de P.S., and Lima, L.N.G.C., 2021. Risk factors associated with the severity of COVID-19 in a region of the Brazilian Amazon. Scientific Reports 11, 20569. https://doi.org/10.1038/s41598-021-00009-y

SARS-CoV-2 variant classifications and definitions [WWW Document], n.d. URL https://stacks.cdc.gov/view/cdc/105817 (accessed 8.23.24).

Sathyapalan, D.T., Nair, S.G., Prasanna, P., A, A., Sathyan, G., Joy, H., Mukundan, R.C., Kulirankal, K.G., Moni, M., and Nampoothiri, V., 2024. Exploring COVID-19 vaccine hesitancy in unvaccinated adults within a semi-urban population of South India: A qualitative investigation. Clinical Epidemiology and Global Health 29, 101739. https://doi.org/10.1016/j.cegh.2024.101739

Sayedahmed, E.E., Elkashif, A., Alhashimi, M., Sambhara, S., and Mittal, S.K., 2020. Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines. Vaccines 8. https://doi.org/10.3390/vaccines8040574

Senefeld J.W., Franchini M., Mengoli C., Cruciani M., Zani M., Gorman E.K., Focosi D., Casadevall A., and Joyner M.J., 2023. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA Network Open 6, e2250647–e2250647. https://doi.org/10.1001/jamanetworkopen.2022.50647

Seyed Alinaghi S., Karimi A., Barzegary A., Mojdeganlou H., Vahedi F., Mirghaderi S.P., Shobeiri P., Ramezani M., Yousefi Konjdar P., Mirzapour P., Tantuoyir M.M., Mehraeen E., Dadras O., and Voltarelli F., 2022. COVID-19 mortality in patients with immunodeficiency and its predictors: a systematic review. Eur J Med Res 27, 195. https://doi.org/10.1186/s40001-022-00824-7

Shields A.M, Anantharachagan A., Arumugakani G., Baker K., Bahal S., Baxendale H., Bermingham W., Bhole M., Boules E., Bright P., Chopra C., Cliffe L., Cleave B., Dempster J., Devlin L., Dhalla F., Diwakar L., Drewe E., Duncan C., Dziadzio M., Elcombe S., Elkhalifa S., Gennery A., Ghanta H., Goddard S., Grigoriadou S., Hackett S., Hayman G., Herriot R., Herwadkar A., Huissoon A., Jain R., Jolles S., Johnston S., Khan S., Laffan J., Lane P., Leeman L., Lowe D.M., Mahabir S., Lochlainn D.J.M., McDermott E., Misbah S., Moghaddas F., Morsi H., Murng S., Noorani S., O’Brien R., Patel S., Price A., Rahman T., Seneviratne S., Shrimpton A., Stroud C., Thomas M., Townsend K., Vaitla P., Verma N., Williams A., Burns S.O., Savic S., and Richter A.G., 2022. Outcomes following SARS-CoV-2 infection in patients with primary and secondary immunodeficiency in the UK. Clinical and Experimental Immunology 209, 247–258. https://doi.org/10.1093/cei/uxac008

Shields A.M., Burns S.O., Savic S., Richter A.G., Anantharachagan A., Arumugakani G., Baker K., Bahal S., Bermingham W., Bhole M., Boules E., Bright P., Burns S., Cleave B., Dempster J., Devlin L., Dhalla F., Drewe E., Duncan C. G., Dziadzio M., Elkhalifa S., Gennery A., Goddard S., Grigoriadou S., Hayman G., Herwadkar A., Huissoon A., Jain R., Jolles S., Johnston S., Leeman L., Mahabir S., MacLochlainn D., McDermott E., Misbah S., Morsi H., Murng S., Noorani S., O’Brien R., Patel S., Price A., Richter A., Savic S., Seneviratne S., Shields A., Shrimpton A., Stroud C., Vaitla P., and Verma N., 2021. COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. Journal of Allergy and Clinical Immunology 147, 870-875.e1. https://doi.org/10.1016/j.jaci.2020.12.620

Shields A.M., Faustini S.E., Hill H.J., Al-Taei S., Tanner C., Ashford F., Workman S., Moreira F., Verma N., Wagg H., Heritage G., Campton N., Stamataki Z., Klenerman P., Thaventhiran J.E.D., Goddard S., Johnston S., Huissoon A., Bethune C., Elcombe S., Lowe D.M., Patel S.Y., Savic S., Burns S.O., Richter A.G., Ahmed Z., Bancroft H., Bates M., Clifford H., Davis G., Dasgin J., Dinally M., Dhalla F., Efstathiou E., Elkhalifa S., Gompels M., Hartl D., Hoque M., Heritage E., Hughes D., Ivory A., Jain R., Kelly S., McCarthy T., McGee C., Mullan D., Morsi H., O’Grady E., Page S., Peters N., Plant T., Shajidevadas A., Slowinsksa M., Suleiman Z., Townsend N., Trinham C., Wareham S., and Walder S., 2022. SARS-CoV-2 Vaccine Responses in Individuals with Antibody Deficiency: Findings from the COV-AD Study. Journal of Clinical Immunology 42, 923–934. https://doi.org/10.1007/s10875-022-01231-7

Shoham, S., Batista, C., Ben Amor, Y., Ergonul, O., Hassanain, M., Hotez, P., Kang, G., Kim, J.H., Lall, B., Larson, H.J., Naniche, D., Sheahan, T., Strub-Wourgaft, N., Sow, S.O., Wilder-Smith, A., Yadav, P., and Bottazzi, M.E., and Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force, 2023. Vaccines and therapeutics for immunocompromised patients with COVID-19. EClinicalMedicine 59, 101965. https://doi.org/10.1016/j.eclinm.2023.101965

Soresina A., Moratto D., Chiarini M., Paolillo C., Baresi G., Focà E., Bezzi M., Baronio B., Giacomelli M., and Badolato R., 2020. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatric Allergy and Immunology 31, 565–569. https://doi.org/10.1111/pai.13263

Sowers K.L. and Galantino M.L., 2022. Living with primary immunodeficiency disease during the Covid-19 pandemic. J Public Health (Berl.) 30, 2753–2760. https://doi.org/10.1007/s10389-021-01545-7

Subauste C.S., 2006. Primary immunodeficiencies and susceptibility to parasitic infections. Parasite Immunology 28, 567–575. https://doi.org/10.1111/j.1365-3024.2006.00890.x

Tangye S.G., Abel L., Al-Muhsen S., Aiuti A., Al-Muhsen S., Al-Mulla F., Anderson M.S., Andreakos E., Novelli A., Arias A.A., Feldman H.B., Belot A., Biggs C.M., Bousfiha A.A., Brodin P., Christodoulou J., Condino-Neto A., Dalgard C.L., Espinosa-Padilla S., Fellay J., Flores C., Franco J.L., Froidure A., Haerynck F., Halwani R., Hammarström L., Henrickson S. E., Hsieh E. W. Y., Itan Y., Karamitros T., Lau Y.-L., Mansouri D., Meyts I., Mogensen T.H., Morio T., Ng L.F.P., Notarangelo L.D., Novelli G., Okada S., Ozcelik T., Pan-Hammarström Q., Perez de Diego R., Prando C., Pujol A., Renia L., Resnick I., Rodríguez-Gallego C., Sancho-Shimizu V., Seppänen M.R.J., Shcherbina A., Snow A.L., Soler-Palacín P., Spaan A. N., Tancevski I., Tangye S.G., Tayoun A.A., Temel S.G., Turvey S.E., Uddin M.J., Vinh D.C., Zatz M., Okamoto K., Pelin D.S., Pesole G., van de Beek D., Colobran R., Wauters J., Su H.C., and Casanova J.-L., 2023. Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. Journal of Allergy and Clinical Immunology 151, 818–831. https://doi.org/10.1016/j.jaci.2022.11.010

Teijaro J.R. and Farber D.L., 2021. COVID-19 vaccines: modes of immune activation and future challenges. Nature Reviews Immunology 21, 195–197. https://doi.org/10.1038/s41577-021-00526-x

Viana R., Moyo S., Amoako D.G., Tegally H., Scheepers C., Althaus C.L., Anyaneji U.J., Bester P.A., Boni M.F., Ch,M., Choga W.T., Colquhoun R., Davids M., Deforche K., Doolabh D., du Plessis L., Engelbrecht S., Everatt J., Giandhari J., Giovanetti M., Hardie D., Hill V., Hsiao N.-Y., Iranzadeh A., Ismail A., Joseph C., Joseph R., Koopile L., Kosakovsky Pond S.L., Kraemer M.U.G., Kuate-Lere L., Laguda-Akingba O., Lesetedi-Mafoko O., Lessells R. J., Lockman S., Lucaci A. G., Maharaj A., Mahlangu B., Maponga T., Mahlakwane K., Makatini Z., Marais G., Maruapula D., Masupu K., Matshaba M., Mayaphi S., Mbhele N., Mbulawa M. B., Mendes A., Mlisana K., Mnguni A., Mohale T., Moir M., Moruisi K., Mosepele M., Motsatsi G., Motswaledi M. S., Mphoyakgosi T., Msomi N., Mwangi P.N., Naidoo Y., Ntuli N., Nyaga M., Olubayo L., Pillay S., Radibe B., Ramphal Y., Ramphal U., San J.E., Scott L., Shapiro R., Singh L., Smith-Lawrence P., Stevens W., Strydom A., Subramoney K., Tebeila N., Tshiabuila D., Tsui J., van Wyk S., Weaver S., Wibmer C.K., Wilkinson E., Wolter N., Zarebski A.E., Zuze B., Goedhals D., Preiser W., Treurnicht F., Venter M., Williamson C., Pybus O.G., Bhiman J., Glass A., Martin D.P., Rambaut A., Gaseitsiwe S., von Gottberg A., and de Oliveira T., 2022. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature 603, 679–686. https://doi.org/10.1038/s41586-022-04411-y

Vindegaard N. and Benros M.E., 2020. COVID-19 pandemic and mental health consequences: Systematic review of the current evidence. Brain, Behavior, and Immunity 89, 531–542. https://doi.org/10.1016/j.bbi.2020.05.048

V’kovski P., Kratzel A., Steiner S., Stalder H., and Thiel V., 2021. Coronavirus biology and replication: implications for SARS-CoV-2. Nature Reviews Microbiology 19, 155–170. https://doi.org/10.1038/s41579-020-00468-6

Volk A., Covini-Souris C., Kuehnel D., De Mey C., Römisch J., and Schmidt T., 2022. SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin. BioDrugs 36, 41–53. https://doi.org/10.1007/s40259-021-00511-9

Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., Bibi S., Briner C., Cicconi P., Collins A.M., Colin-Jones R., Cutl,C.L., Darton T.C., Dheda K., Duncan C.J.A., Emary K.R.W., Ewer K.J., Fairlie L., Faust S.N., Feng S., Ferreira D.M., Finn A., Goodman A.L., Green C.M., Green C.A., Heath P.T., Hill C., Hill H., Hirsch I., Hodgson S.H.C., Izu A., Jackson S., Jenkin D., Joe C.C.D., Kerridge S., Koen A., Kwatra G., Lazarus R., Lawrie A. M., Lelliott A., Libri V., Lillie P.J., Mallory R., Mendes A.V.A., Milan E.P., Minassian A.M., McGregor A., Morrison H., Mujadidi Y.F., Nana A., O’Reilly P.J., Padayachee S.D., Pittella A., Plested E., Pollock K.M., Ramasamy M.N., Rhead S., Schwarzbold A.V., Singh N., Smith A., Song R., Snape M.D., Sprinz E., Sutherl,R.K., Tarrant R., Thomson E.C., Török M.E., Toshner M., Turner D.P.J., Vekemans J., Villafana T.L., Watson M.E.E., Williams C.J., Douglas A.D., Hill A.V.S., Lambe T., Gilbert S.C., Pollard A.J., Aban M., Abayomi F., Abeyskera K., Aboagye J., Adam M., Adams K., Adamson J., Adelaja Y.A., Adewetan G., Adlou S., Ahmed K., Akhalwaya Y., Akhalwaya S., Alcock A., Ali A., Allen E.R., Allen L., Almeida T.C.D.S.C., and Zuidewind P., 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet 397, 99–111. https://doi.org/10.1016/S0140-6736(20)32661-1

Weifenbach N., Jung A., and Lötters S., 2021. COVID-19 infection in CVID patients: What we know so far. Immunity, Inflammation and Disease 9, 632–634. https://doi.org/10.1002/iid3.450

Wolter N., Jassat W., Walaza S., Welch R., Moultrie H., Groome M., Amoako D.G., Everatt J., Bhiman J.N., Scheepers C., Tebeila N., Chiwandire N., du Plessis M., Govender N., Ismail A., Glass A., Mlisana K., Stevens W., Treurnicht F.K., Makatini Z., Hsiao N.-Y., Parboosing R., Wadula J., Hussey H., Davies M.-A., Boulle A., von Gottberg A., and Cohen C., 2022. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. The Lancet 399, 437–446. https://doi.org/10.1016/S0140-6736(22)00017-4

Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Hu, Y., Song, Z.-G., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., Yuan, M.-L., Zhang, Y.-L., Dai, F.-H., Liu, Y., Wang, Q.-M., Zheng, J.-J., Xu, L., Holmes, E.C., Zhang, and Y.-Z., 2020. Complete genome characterisation of a novel coronavirus associated with severe human respiratory disease in Wuhan, China. bioRxiv 2020.01.24.919183. https://doi.org/10.1101/2020.01.24.919183

Yang Z., Zhang Shuo, Tang Y.-P., Zhang Sai, Xu D.-Q., Yue S.-J., and Liu Q.-L., 2022. Clinical Characteristics, Transmissibility, Pathogenicity, Susceptible Populations, and Re-infectivity of Prominent COVID-19 Variants. Aging and disease 13, 402. https://doi.org/10.14336/AD.2021.1210

Yüce M., Filiztekin E., and Özkaya K.G., 2021. COVID-19 diagnosis — A review of current methods. Biosensors and Bioelectronics 172, 112752. https://doi.org/10.1016/j.bios.2020.112752

Zhang J., Dong X., Liu G., and Gao Y., 2023. Risk and Protective Factors for COVID-19 Morbidity, Severity, and Mortality. Clinical Reviews in Allergy & Immunology 64, 90–107. https://doi.org/10.1007/s12016-022-08921-5

Zhang Q., Bastard P., Liu Z., Le Pen J., Moncada-Velez M., Chen J., Ogishi M., Sabli I.K.D., Hodeib S., Korol C., Rosain J., Bilguvar K., Ye J., Bolze A., Bigio B., Yang R., Arias A.A., Zhou Q., Zhang Y., Onodi F., Korniotis S., Karpf L., Philippot Q., Chbihi M., Bonnet-Madin L., Dorgham K., Smith N., Schneider W.M., Razooky B.S., Hoffmann H.-H., Michailidis E., Moens L., Han J.E., Lorenzo L., Bizien L., Meade P., Neehus A.-L., Ugurbil A.C., Corneau A., Kerner G., Zhang P., Rapaport F., Seeleuthner Y., Manry J., Masson C., Schmitt Y., Schlüter A., Le Voyer T., Khan T., Li J., Fellay J., Roussel L., Shahrooei M., Alosaimi M.F., Mansouri D., Al-Saud H., Al-Mulla F., Almourfi F., Al-Muhsen S.Z., Alsohime F., Al Turki S., Hasanato R., van de Beek D., Biondi A., Bettini L.R., D’Angio’ M., Bonfanti P., Imberti L., Sottini A., Paghera S., Quiros-Roldan E., Rossi C., Oler A.J., Tompkins M.F., Alba C., Vandernoot I., Goffard J.-C., Smits G., Migeotte I., Haerynck F., Soler-Palacin P., Martin-Nalda A., Colobran R., Morange P.-E., Keles S., Çölkesen F., Ozcelik T., Yasar K.K., Senoglu S., Karabela Ş.N., Rodríguez-Gallego C., Novelli G., Hraiech S., Tandjaoui-Lambiotte Y., Duval X., Laouénan C., Snow A. L., Dalgard C.L., Milner J.D., Vinh D.C., and Zhang X., 2020. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570. https://doi.org/10.1126/science.abd4570

Zhang Qianhui, Wei Y., Chen M., Wan Q., and Chen X., 2020. Clinical analysis of risk factors for severe COVID-19 patients with type 2 diabetes. Journal of Diabetes and its Complications 34, 107666. https://doi.org/10.1016/j.jdiacomp.2020.107666

Zhou J.J., Jin C., Leang Z.X., Chatelier J., Godsell J., Tsang S., Douglass J.A., Yong M.K., Slavin M., Bryant V.L., Slade C.A., and Chan S., 2024. A single-center experience of COVID-19 infection in patients with primary immunodeficiency. Journal of Allergy and Clinical Immunology: Global 3, 100241. https://doi.org/10.1016/j.jacig.2024.100241

Zhu N., Zhang D., Wang W., Li X., Yang B., Song J., Zhao X., Huang B., Shi W., Lu R., Niu P., Zhan F., Ma X., Wang D., Xu W., Wu G., Gao G.F., and Tan W., 2020. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine 382, 727–733. https://doi.org/10.1056/NEJMoa2001017